Home

Fixation device to secure bone fragment of tibial tuberosity to native bone after osteotomy surgical procedure. Background:
Standard osteotomy techniques to join the tibial tubercle fragment to native bone include screw fixation alone or fixation with wire or suture, which are not reliable methods to holding the bone in place to avoid displacement post-operatively and possibly leading to non-union, malunion, extensor weakness, extensor lag, or complete loss of active knee extension.Technology Overview:  
Orthopedic oncology and joint reconstruction expert at Upstate Medical University has designed a device that secures the bone fragment of tibial tuberosity to the native bone using custom-made plates, screws and suture/wires after osteotomy and mobilization of the tuberosity and associated patellar tendon. https://suny.technologypublisher.com/files/sites/adobestock_322821442_(002).jpeg Advantages:  
•    Improves fixation of the tibial tubercle fragment by improving bone to bone healing and normal restoration of the knee.
•    Reduces rate of revision surgery.
•    Minimizes surgery time.  
Intellectual Property Summary:
Patent Pending US 18/236,678Stage of Development:
TRL 3 - Experimental proof of concept Licensing Status:
This technology is available for licensing.
 
 

An adapter that expedites bone surgery by making hand-held retractors self-retaining.  Background: Orthopedic surgeons require unfettered access to exposed bone. That means keeping the skin, subcutaneous fat, tissues, and muscles out of the way with retractors. Currently, there are two common types of retractors for this purpose—self-retaining retractors, which stay open on their own, and hand-held retractors, which need an assistant to hold them. The current disclosure describes an adapter that couples the hand-held retractors to the self-retaining retractor, enabling the hand-held retractors to be self-retaining. This eliminates the need for an assistant and affords the surgeon better exposure to the bone, thereby increasing the efficiency of surgery while reducing cost. Technology Overview:  The device combines the functions of a hand-held retractor, used on soft tissue near the bone, with those of a self-retaining retractor, used on surface levels like skin and subcutaneous fat. The device consists of two sleeves slipped over the arms of the hand-held retractors. The inner surfaces of the sleeves have inverted V-shaped projections to capture the tips of the self-retaining retractor. When the tips are inserted into the projections on the sleeves, the self-retaining retractor secures the hand-held retractors and keeps them open. The adapter can be used with equipment that is readily available in every orthopedic operating room. It will be made of sterilizable metal or durable plastic to guarantee years of use.   https://suny.technologypublisher.com/files/sites/110-20302.jpg Advantages:

• Increases efficiency of surgery.
• Reduces costs.

This technology uses a gentle electrical current to deliver antifibrotic drugs like collagenase directly into fibrotic tissues, such as the bladder wall, enabling noninvasive, targeted treatment of fibrosis and improving tissue function without surgery. Background:
Fibrosis of the bladder wall, particularly in the context of neurogenic bladder, represents a significant clinical challenge in urology. Neurogenic bladder, often resulting from conditions such as spinal cord injury or spina bifida, leads to chronic dysfunction of bladder emptying and storage. Over time, repeated overdistention, infection, and inflammation can trigger excessive collagen deposition within the bladder wall, resulting in fibrosis. This pathological remodeling reduces bladder compliance, raises intravesical pressures, and increases the risk of incontinence, vesicoureteral reflux, and even kidney damage. The need for effective therapies is acute, as progressive fibrosis can lead to irreversible loss of bladder function and severe complications, impacting quality of life and long-term health outcomes. Current approaches to managing bladder fibrosis are limited and largely inadequate. There are no approved pharmacologic treatments capable of reversing established fibrosis or restoring normal tissue compliance. Standard medical management, such as antispasmodics and catheter drainage, only addresses symptoms without targeting the underlying fibrotic process. When conservative measures fail, patients often require invasive procedures like Botox injections or surgical bladder augmentation, both of which carry significant morbidity and do not directly address the excessive collagen buildup. Topical instillation of drugs is ineffective due to the impermeability of the urothelium, while systemic delivery of antifibrotic agents is hampered by poor tissue targeting and potential toxicity. As a result, there is a critical unmet need for a safe, effective, and targeted method to deliver therapeutic agents directly into fibrotic bladder tissue to halt or reverse disease progression.Technology Overview:  
This technology is a noninvasive, targeted drug delivery system designed to treat fibrotic diseases, with a primary focus on bladder wall fibrosis associated with neurogenic bladder. It employs Electromotive Drug Administration (EMDA) to deliver therapeutic macromolecules directly into fibrotic tissues. The system works by applying a low-intensity electrical current through an intravesical catheter equipped with an active electrode, while a return electrode is placed on the abdominal skin. This electrical gradient increases urothelial permeability and actively drives charged therapeutic agents through the bladder wall, enabling deep tissue penetration that passive delivery methods cannot achieve. The approach allows for precise, localized degradation of pathological collagen buildup, restoring tissue compliance and function while minimizing systemic exposure. The platform is adaptable for co-administration of other antifibrotic agents, and can be paired with adjunct modalities such as ultrasound, further enhancing its therapeutic potential. What differentiates this technology is its ability to overcome the natural barriers that have historically limited the effectiveness of pharmacologic treatments for fibrosis in mucosal-lined organs. Unlike current options, which are largely invasive, this system provides a non-surgical, focal therapy that directly targets and remodels fibrotic tissue. Its use of EMDA for collagenase delivery is a novel application, leveraging clinically validated infrastructure to enable safe, controlled, and repeatable administration of large macromolecules. The platform’s flexibility allows for combination therapies and adaptation to a range of fibrotic conditions beyond the bladder, including urethral stricture, Peyronie’s disease, and even pulmonary or post-surgical fibrosis. This versatility, combined with its noninvasive nature and compatibility with existing clinical systems, positions the technology as a significant advancement with broad clinical and commercial impact. https://suny.technologypublisher.com/files/sites/adobestock_1728653231.jpeg
Photo for reference only, not a depiction of the invention.Advantages:  
•    Enables noninvasive, targeted delivery of collagenase and antifibrotic agents directly into fibrotic bladder tissue, overcoming urothelial barriers.
•    Restores bladder compliance and function by degrading pathological collagen buildup, addressing a currently untreatable condition.
•    Minimizes systemic exposure and off-target effects through localized, controlled drug administration.
•    Adaptable for combination therapies with secondary antifibrotic agents and adjunct modalities like ultrasound or shockwave therapy.
•    Uses safe, clinically validated electrical parameters and delivery infrastructure, facilitating clinical adoption.
•    Extensible to other fibrotic urogenital disorders and potentially to fibrosis in other mucosal-lined tissues.
•    Offers a non-surgical alternative to invasive procedures, reducing patient morbidity and healthcare costs.
•    Supports monitoring of therapeutic response via integrated biomarkers for optimized treatment. Applications:  
•    Bladder fibrosis treatment
•    Urethral stricture therapy
•    Peyronie’s disease intervention
•    Post-surgical adhesion prevention
•    Localized gastrointestinal fibrosis therapy Intellectual Property Summary:
Patent PendingStage of Development :
Inquire for more informationLicensing Status:
This technology is available for licensing.
 

This technology is a computer vision-based software platform that enables real-time human movement analysis, providing physical therapists and trainers with objective feedback and progress tracking through a standard webcam. Background:
Traditional physical therapy and fitness training often rely on subjective visual assessments, which can limit the accuracy and consistency of movement analysis. Recognizing this challenge, the invention was developed to introduce an objective, data-driven solution that enhances motor learning and rehabilitation outcomes by leveraging advancements in computer vision and pose estimation technologies.Technology Overview:  
This innovative software platform uses computer vision algorithms to analyze human movement in real time via a standard webcam. At its core, the system employs advanced pose estimation techniques, such as those found in open-source libraries like MediaPipe, to track joint angles and assess the quality of movements. By integrating theories of motor control and motor learning, the platform delivers precise feedback designed to optimize movement retraining, crucial for both rehabilitation and fitness improvement. The technology features automated repetition counting, detailed feedback on individual performance, and comprehensive summaries after each session, enabling users and professionals to monitor progress effectively. It supports use in both clinical environments and remote settings, offering accessibility and flexibility to a broad range of users. The platform's architecture primarily consists of newly developed code complemented by established video processing tools like OpenCV, ensuring robust performance and accuracy. Designed to address significant gaps in current physical therapy and fitness markets, this solution transforms subjective observations into actionable, evidence-based insights. Future enhancements include cloud-based scaling options and compatibility with health record systems and wearable devices, extending its applicability and integration within modern healthcare ecosystems. https://suny.technologypublisher.com/files/sites/adobestock_1666031996.jpegAdvantages:  
•    Provides objective and precise movement analysis compared to subjective visual assessments.
•    Real-time feedback facilitates immediate correction and more effective motor learning.
•    Uses accessible hardware—a standard webcam—allowing broad adoption without specialized equipment.
•    Supports both clinical and remote use cases, enhancing flexibility and convenience.
•    Automated features such as repetition counting reduce manual tracking efforts.
•    Comprehensive post-session data assists in monitoring long-term progress and rehabilitation outcomes.
•    Incorporates scientifically grounded motor control theories to optimize movement retraining.
•    Future cloud integration promises scalability and seamless interoperability with health technologies. Applications:  
•    Physical therapy clinics for precise movement assessment and rehabilitation monitoring.
•    Fitness training environments where coaches can provide objective, data-driven feedback.
•    Remote rehabilitation programs enabling patients to perform exercises at home with professional oversight.
•    Sports performance analysis to optimize athletes' movement techniques and reduce injury risks.
•    Integration with wearable devices and electronic health records for comprehensive health management.
•    Research settings studying motor control and learning through consistent and repeatable movement data. Intellectual Property Summary:
Copyright, patents availableStage of Development:
TRL 6Licensing Status:
This technology is available for licensing.